MITF and melanoma: There is growing evidence that the slow cycling phenotype in melanoma identifies a subset of cells associated with resistance to various types of treatments: these cells are characterized by a de-differentiated state, low MITF expression, activation of signaling pathways such as WNT5A and EGFR, and high expression of JARID1B protein [261].